Tiziana Life Sciences (US) (TLSA) has released an update.
Tiziana Life Sciences has applied for FDA Orphan Drug Designation for its intranasal foralumab, a potential breakthrough treatment for non-active secondary progressive Multiple Sclerosis (na-SPMS). The drug, which showed promise in clinical studies by improving or stabilizing symptoms in patients, could be the first of its kind to receive such a designation. The company touts the designation as a path to exclusive marketing and developmental incentives, underlining its significance for Tiziana’s shareholders and the medical community.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
